BIOCON LIMITED.

Biocon Limited's Q1 FY27 earnings conference call highlighted the company's strategic and financial strength, with management reporting a 10% year-on-year growth in operating revenue. The biopharmaceuticals segment grew by 17%, while services revenue declined by 16%. EBITDA was reported at INR902 crores with a margin of 21%, and net profit before exceptionals increased by 245% year-on-year to INR145 crores. Management emphasized the successful integration of biosimilars and generics, with significant launches in North America and Europe. The biosimilars business generated INR2,855 crores in revenue, a 16% increase, while generics revenue reached INR760 crores, up 21%. Syngene's performance was impacted by lower demand from a key client, but management expressed confidence in future growth driven by new product launches and improved operational efficiencies. The call concluded with management reiterating their focus on profitable growth and cash generation.

Management emphasized strong growth and strategic positioning across key markets.